Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 18/20 | 1.00 |
| ▸ | MMP3 | P08254 | 18/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588532 | 0.91 | MMP2 (0.84) | MMP2MMP3CCNT1CDK9MMP1 | |
| SCHEMBL6586903 | 0.91 | MMP3 (1.00) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL6587197 | 0.91 | MMP3 (0.83) | MMP2MMP3CCNT1CDK9MMP1 | |
| SCHEMBL6586239 | 0.90 | MMP3 (0.81) | MMP2MMP3 | |
| SCHEMBL6586398 | 0.88 | MMP3 (1.00) | MMP2MMP3CCNT1CDK9MMP1 | |
| SCHEMBL6584456 | 0.86 | MMP3 (1.00) | MMP2MMP3MMP9 | |
| SCHEMBL6586191 | 0.86 | MMP2 (0.76) | MMP2MMP3CCNT1CDK9MMP1 | |
| SCHEMBL6586215 | 0.86 | MMP3 (1.00) | MMP2MMP3 | |
| SCHEMBL6585982 | 0.85 | MMP3 (0.86) | MMP2MMP3 | |
| SCHEMBL6584535 | 0.84 | MMP3 (1.00) | MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | claimed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | claimed |
| EP-1036062-B1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LTD (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6495568-B1 | TREATMENT OF TISSUE ULCERATION, WOUND REPAIR AND SKIN DISEASES | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |